Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. M. Garcia-Garcia, T. Rodrigo, M. Casals, J. Ruiz-Manzano, T. Pascual, J. Cayla, G. T. B. Trabajo (Aviles, Barcelona, Gijon, Spain). Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain. Eur Respir J 2014; 44: Suppl. 58, 2683

Member's Comments

No comment yet.

Related content which might interest you: Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Effect of anti-tuberculosis treatment on body composition during the intensive phase Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Study on drug sensitivity patterns in tuberculosis in tertiary care in Mumbai Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Is there a need for prolonged follow up in mono-drug resistant TB? Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016 Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Home based tuberculosis (TB) care program Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015